The Diagnosis and Management of Bipolar I and II Disorders: Clinical Practice Update

Mayo Clinic Proceedings

Volumn 92, Issue 10, 2017, Pages 1532-1551

  Bobo, William V ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; CARBAMAZEPINE; CARIPRAZINE; CHLORPROMAZINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM; ZIPRASIDONE;

BEHAVIOR ASSESSMENT; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CHRONIC DISEASE; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL PRACTICE; COMORBIDITY; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; HYPOMANIA; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR DEPRESSION; MOOD DISORDER QUESTIONNAIRE; ONSET AGE; PATIENT REFERRAL; PSYCHIATRIC DIAGNOSIS; PSYCHIATRIC TREATMENT; PSYCHOPHARMACOTHERAPY; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; RAPID CYCLING BIPOLAR DISORDER; REVIEW; RISK FACTOR; SOCIAL PSYCHOLOGY; SUICIDE; TREATMENT OUTCOME; DISEASE MANAGEMENT; PSYCHOLOGICAL RATING SCALE;

BIPOLAR DISORDER; DISEASE MANAGEMENT; HUMANS; PSYCHIATRIC STATUS RATING SCALES;

EID: 85028871344     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2017.06.022     Document Type: Review

References (152)

1. Rihmer, Z., Angst, J., Mood disorders: epidemiology., 9th ed. Sadock, B.J., Sadock, S.V., Ruiz, P., (eds.) Textbook of Psychiatry, Vol 1, 2009, Lippincott Williams & Wilkins, Philadelphia, PA, 1645–1652.
2. Bauer, M., Pfennig, A., Epidemiology of bipolar disorders. Epilepsia 46:suppl 4 (2005), 8–13.
3. Angst, J., Gamma, A., Lewinsohn, P., The evolving epidemiology of bipolar disorder. World Psychiatry 1:3 (2002), 146–148.
4. Kessler, R.C., Chiu, W.T., Demler, O., et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:6 (2005), 617–627.
5. Hirschfeld, R.M., Calabrese, J.R., Weissman, M.M., et al. Screening for bipolar disorder in the community. J Clin Psychiatry 64:1 (2003), 53–59.
6. Vos, T., Flaxman, A.D., Naghavi, M., et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:9859 (2012), 2163–2196.
7. Whiteford, H.A., Harris, M.G., McKeon, G., et al. Estimating remission from untreated major depression: a systematic review and meta-analysis. Psychol Med 43:8 (2013), 1569–1585.
8. Judd, L.L., Akiskal, H.S., Schettler, P.J., et al. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry 62:12 (2005), 1322–1330.
9. Scott, J., Leboyer, M., Consequences of delayed diagnosis of bipolar disorders. Encephale 37:suppl 3 (2011), S173–S175.
10. Manning, J.S., Haykal, R.F., Connor, P.D., Akiskal, H.S., On the nature of depressive and anxious states in a family practice setting: the high prevalence of bipolar II and related disorders in a cohort followed longitudinally. Compr Psychiatry 38:2 (1997), 102–108.
11. Scola, G., Andreazza, A.C., Current state of biomarkers in bipolar disorder. Curr Psychiatry Rep, 16(12), 2014, 514.
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). 5th ed., 2013, American Psychiatric Publishing, Arlington, VA, 123–154.
13. Suppes, T., Leverich, G.S., Keck, P.E., et al. The Stanley Foundation Bipolar Treatment Outcome Network, II: Demographics and illness characteristics of the first 261 patients. J Affect Disord 67:1-3 (2001), 45–59.
14. Judd, L.L., Akiskal, H.S., Schettler, P.J., et al. The comparative clinical phenotype and long term longitudinal episode course of bipolar I and II: a clinical spectrum or distinct disorders?. J Affect Disord 73:1-2 (2003), 19–32.
15. Kennedy, N., Boydell, J., Kalidindi, S., et al. Gender differences in incidence and age at onset of mania and bipolar disorder over a 35-year period in Camberwell, England. Am J Psychiatry 162:2 (2005), 257–262.
16. Tohen, M., Zarate, C.A. Jr., Hennen, J., et al. The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry 160:12 (2003), 2099–2107.
17. Goldberg, J.F., Harrow, M., Consistency of remission and outcome in bipolar and unipolar mood disorders: a 10-year prospective follow-up. J Affect Disord 81:2 (2004), 123–131.
18. Judd, L.L., Akiskal, H.S., Schettler, P.J., et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 59:6 (2002), 530–537.
19. Roshanaei-Moghaddam, B., Katon, W., Premature mortality from general medical illnesses among persons with bipolar disorder: a review. Psychiatr Serv 60:2 (2009), 147–156.
20. Crump, C., Sundquist, K., Winkleby, M.A., Sundquist, J., Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry 70:9 (2013), 931–939.
21. Hayes, J.F., Miles, J., Walters, K., King, M., Osborn, D.P., A systematic review and meta-analysis of premature mortality in bipolar affective disorder. Acta Psychiatr Scand 131:6 (2015), 417–425.
22. Ramsey, C.M., Spira, A.P., Mojtabai, R., et al. Lifetime manic spectrum episodes and all-cause mortality: 26-year follow-up of the NIMH Epidemiologic Catchment Area Study. J Affect Disord 151:1 (2013), 337–342.
23. Callaghan, R.C., Veldhuizen, S., Jeysingh, T., et al. Patterns of tobacco-related mortality among individuals diagnosed with schizophrenia, bipolar disorder, or depression. J Psychiatr Res 48:1 (2014), 102–110.
24. Kleinman, L., Lowin, A., Flood, E., et al. Costs of bipolar disorder. Pharmacoeconomics 21:9 (2003), 601–622.
25. Dean, B.B., Gerner, D., Gerner, R.H., A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder. Curr Med Res Opin 20:2 (2004), 139–154.
26. Ostacher, M.J., Nierenberg, A.A., Iosifescu, D.V., et al. Correlates of subjective and objective burden among caregivers of patients with bipolar disorder. Acta Psychiatr Scand 118:1 (2008), 49–56.
27. Stensland, M.D., Jacobson, J.G., Nyhuis, A., Service utilization and associated direct costs for bipolar disorder in 2004: an analysis in managed care. J Affect Disord 101:1-3 (2007), 187–193.
28. Sachs, G.S., Nierenberg, A.A., Calabrese, J.R., et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 356:17 (2007), 1711–1722.
29. Goldberg, J.F., Garno, J.L., Harrow, M., Long-term remission and recovery in bipolar disorder: a review. Curr Psychiatry Rep 7:6 (2005), 456–461.
30. Culpepper, L., Misdiagnosis of bipolar depression in primary care practices. J Clin Psychiatry, 75(3), 2014, e05 http://www.psychiatrist.com/jcp/article/Pages/2014/v75n03/v75n03e05.aspx Accessed on June 17, 2017.
31. Berk, M., Dodd, S., Berk, L., Opie, J., Diagnosis and management of patients with bipolar disorder in primary care. Br J Gen Pract 55:518 (2005), 662–664.
32. Hirschfeld, R.M., Cass, A.R., Holt, D.C., Carlson, C.A., Screening for bipolar disorder in patients treated for depression in a family medicine clinic. J Am Board Fam Pract 18:4 (2005), 233–239.
33. Goldberg, J.F., Garno, J.L., Callahan, A.M., et al. Overdiagnosis of bipolar disorder among substance use disorder in patients with mood instability. J Clin Psychiatry 69:11 (2008), 1751–1757.
34. Zimmerman, M., Ruggero, C.J., Chelminski, I., Young, D., Is bipolar disorder overdiagnosed?. J Clin Psychiatry 69:6 (2008), 935–940.
35. Hirschfeld, R.M., Lewis, L., Vornik, L.A., Perceptions and impact of bipolar disorder: how far have we really come? results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry 64:2 (2003), 161–174.
36. Zimmerman, M., Ruggero, C.J., Chelminski, I., Young, D., Psychiatric diagnoses in patients previously overdiagnosed with bipolar disorder. J Clin Psychiatry 71:1 (2010), 26–31.
37. Vieta, E., Valenti, M., Mixed states in DSM-5: implications for clinical care, education, and research. J Affect Disord 148:1 (2013), 28–36.
38. Angst, J., Cui, L., Swendsen, J., et al. Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication. Am J Psychiatry 167:10 (2010), 1194–1201.
39. McIntyre, R.S., Lee, Y., Mansur, R.B., A pragmatic approach to the diagnosis and treatment of mixed features in adults with mood disorders. CNS Spectr 21:S1 (2016), 25–33.
40. Mitchell, P.B., Goodwin, G.M., Johnson, G.F., Hirschfeld, R.M., Diagnostic guidelines for bipolar depression: a probabilistic approach. Bipolar Disord 10:1 pt 2 (2008), 144–152.
41. Akiskal, H.S., The dark side of bipolarity: detecting bipolar depression in its pleomorphic expressions. J Affect Disord 84:2-3 (2005), 107–115.
42. Othmer, E., Desouza, C.M., Penick, E.C., et al. Indicators of mania in depressed outpatients: a retrospective analysis of data from the Kansas 1500 study. J Clin Psychiatry 68:1 (2007), 47–51.
43. Aiken, C.B., Weisler, R.H., Sachs, G.S., The Bipolarity Index: a clinician-rated measure of diagnostic confidence. J Affect Disord 177 (2015), 59–64.
44. Li, C.T., Bai, Y.M., Huang, Y.L., et al. Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder: cohort study. Br J Psychiatry 200:1 (2012), 45–51.
45. Sharma, V., Khan, M., Smith, A., A closer look at treatment resistant depression: is it due to a bipolar diathesis?. J Affect Disord 84:2-3 (2005), 251–257.
46. Krishnan, K.R., Psychiatric and medical comorbidities of bipolar disorder. Psychosom Med 67:1 (2005), 1–8.
47. Otto, M.W., Simon, N.M., Wisniewski, S.R., et al. Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders. Br J Psychiatry 189 (2006), 20–25.
48. Nierenberg, A.A., Miyahara, S., Spencer, T., et al. Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity disorder comorbidity in adults with bipolar disorder: data from the first 1000 STEP-BD participants. Biol Psychiatry 57:11 (2005), 1467–1473.
49. Baethge, C., Baldessarini, R.J., Khalsa, H.M., et al. Substance abuse in first-episode bipolar I disorder: indications for early intervention. Am J Psychiatry 162:5 (2005), 1008–1010.
50. Ostacher, M.J., Perlis, R.H., Nierenberg, A.A., et al. Impact of substance use disorders on recovery from episodes of depression in bipolar disorder: prospective data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 167:3 (2010), 289–297.
51. McElroy, S.L., Crow, S., Blom, T.J., et al. Prevalence and correlates of DSM-5 eating disorders in patients with bipolar disorder. J Affect Disord 191 (2016), 216–221.
52. Latalova, K., Prasko, J., Kamaradova, D., et al. Comorbidity bipolar disorder and personality disorders. Neuro Endocrinol Lett 34:1 (2013), 1–8.
53. Kemp, D.E., Sylvia, L.G., Calabrese, J.R., et al. General medical burden in bipolar disorder: findings from the LiTMUS comparative effectiveness trial. Acta Psychiatr Scand 129:1 (2014), 24–34.
54. Perron, B.E., Howard, M.O., Nienhuis, J.K., et al. Prevalence and burden of general medical conditions among adults with bipolar I disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 70:10 (2009), 1407–1415.
55. Sylvia, L.G., Shelton, R.C., Kemp, D.E., et al. Medical burden in bipolar disorder: findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar CHOICE). Bipolar Disord 17:2 (2015), 212–223.
56. Pan, A., Keum, N., Okereke, O.I., et al. Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care 35:5 (2012), 1171–1180.
57. Fagiolini, A., Frank, E., Scott, J.A., et al. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 7:5 (2005), 424–430.
58. Calkin, C., van de Velde, C., Ruzickova, M., et al. Can body mass index help predict outcome in patients with bipolar disorder?. Bipolar Disord 11:6 (2009), 650–656.
59. Kemp, D.E., Gao, K., Chan, P.K., et al. Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome. Bipolar Disord 12:4 (2010), 404–413.
60. Ruzickova, M., Slaney, C., Garnham, J., Alda, M., Clinical features of bipolar disorder with and without comorbid diabetes mellitus. Can J Psychiatry 48:7 (2003), 458–461.
61. Schwartz, T.L., Nihalani, N., Jindal, S., et al. Psychiatric medication-induced obesity: a review. Obes Rev 5:2 (2004), 115–121.
62. Manji, H.K., Lenox, R.H., The nature of bipolar disorder. J Clin Psychiatry 61:suppl 13 (2000), 42–57.
63. Martinowich, K., Schloesser, R.J., Manji, H.K., Bipolar disorder: from genes to behavior pathways. J Clin Invest 119:4 (2009), 726–736.
64. Sassi, R.B., Soares, J.C., Neural circuitry and signaling in bipolar disorder. Kaplan, G.B., Hammer, R.P., (eds.) Brain Circuitry and Signaling in Psychiatry, 2002, American Psychiatric Publishing Inc, Washington, DC, 179–199.
65. Goes, F.S., Genetics of bipolar disorder: recent update and future directions. Psychiatr Clin North Am 39:1 (2016), 139–155.
66. Craddock, N., Sklar, P., Genetics of bipolar disorder. Lancet 381:9878 (2013), 1654–1662.
67. International Schizophrenia Consortium, Purcell, S.M., Wray, N.R., et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460:7256 (2009), 748–752.
68. Houenou, J., Frommberger, J., Carde, S., et al. Neuroimaging-based markers of bipolar disorder: evidence from two meta-analyses. J Affect Disord 132:3 (2011), 344–355.
69. Strakowski, S.M., Adler, C.M., Almeida, J., et al. The functional neuroanatomy of bipolar disorder: a consensus model. Bipolar Disord 14:4 (2012), 313–325.
70. Barnett, J.H., Smoller, J.W., The genetics of bipolar disorder. Neuroscience 164:1 (2009), 331–343.
71. Smoller, J.W., Finn, C.T., Family, twin, and adoption studies of bipolar disorder. Am J Med Genet C Semin Med Genet 123C:1 (2003), 48–58.
72. Lichtenstein, P., Yip, B.H., Bjork, C., et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 373:9659 (2009), 234–239.
73. Alloy, L.B., Abramson, L.Y., Urosevic, S., et al. The psychosocial context of bipolar disorder: environmental, cognitive, and developmental risk factors. Clin Psychol Rev 25:8 (2005), 1043–1075.
74. Hirschfeld, R.M., Williams, J.B., Spitzer, R.L., et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry 157:11 (2000), 1873–1875.
75. Ghaemi, S.N., Miller, C.J., Berv, D.A., et al. Sensitivity and specificity of a new bipolar spectrum diagnostic scale. J Affect Disord 84:2-3 (2005), 273–277.
76. Phelps, J.R., Ghaemi, S.N., Improving the diagnosis of bipolar disorder: predictive value of screening tests. J Affect Disord 92:2-3 (2006), 141–148.
77. Kessler, R.C., Akiskal, H.S., Angst, J., et al. Validity of the assessment of bipolar spectrum disorders in the WHO CIDI 3.0. J Affect Disord 96:3 (2006), 259–269.
78. Drugs that may cause psychiatric symptoms. Med Lett Drugs Ther 50:1301-1302 (2008), 100–103.
79. Freudenreich, O., Schulz, S.C., Goff, D.C., Initial medical workup of first-episode psychosis: a conceptual review. Early Interv Psychiatry 3:1 (2009), 10–18.
80. Rouchell, A.M., Major depression in primary care. Ochsner J 2:2 (2000), 79–84.
81. Smith, M.L., Atypical psychosis. Psychiatr Clin North Am 21:4 (1998), 895–904.
82. Fountoulakis, K.N., Vieta, E., Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. Int J Neuropsychopharmacol 11:7 (2008), 999–1029.
83. Zeller, S.L., Citrome, L., Managing agitation associated with schizophrenia and bipolar disorder in the emergency setting. West J Emerg Med 17:2 (2016), 165–172.
84. Citrome, L., Volavka, J., The psychopharmacology of violence: making sensible decisions. CNS Spectr 19:5 (2014), 411–418.
85. Allen, M.H., Currier, G.W., Carpenter, D., et al. The expert consensus guideline series: treatment of behavioral emergencies 2005. J Psychiatr Pract 11:suppl 1 (2005), 5–108.
86. Cipriani, A., Barbui, C., Salanti, G., Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 378:9799 (2011), 1306–1315.
87. Glue, P., Herbison, P., Comparative efficacy and acceptability of combined antipsychotics and mood stabilizers versus individual drug classes for acute mania: network meta-analysis. Aust N Z J Psychiatry 49:12 (2015), 1215–1220.
88. Grunze, H., Vieta, E., Goodwin, G.M., et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 10:2 (2009), 85–116.
89. Malhi, G.S., Adams, D., Lampe, L., et al. Clinical practice recommendations for bipolar disorder. Acta Psychiatr Scand Suppl(439), 2009, 27–46.
90. Kusumakar, V., Yatham, L., Haslam, D., et al. Treatment of mania, mixed state, and rapid cycling. Can J Psychiatry 42:suppl 2 (1997), 79S–86S.
91. Muzina, D.J., Pharmacologic treatment of rapid cycling and mixed states in bipolar disorder: an argument for the use of lithium. Bipolar Disord 11:suppl 2 (2009), 84–91.
92. Allen, M.H., Hirschfeld, R.M., Wozniak, P.J., et al. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry 163:2 (2006), 272–275.
93. Keck, P.E. Jr., McElroy, S.L., Tugrul, K.C., Bennett, J.A., Valproate oral loading in the treatment of acute mania. J Clin Psychiatry 54:8 (1993), 305–308.
94. Thibault, M., Blume, W.T., Saint-Hilaire, J.-M., et al. Divalproex extended-release versus the original divalproex tablet: results of a randomized, crossover study of well-controlled epileptic patients with primary generalized seizures. Epilepsy Res 50:3 (2002), 243–249.
95. Spina, E., Pisani, F., Perucca, E., Clinically significant pharmacokinetic drug interactions with carbamazepine: an update. Clin Pharmacokinet 31:3 (1996), 198–214.
96. Miura, T., Noma, H., Furukawa, T.A., et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry 1:5 (2014), 351–359.
97. Tangamornsuksan, W., Chaiyakunapruk, N., Somkrua, R., et al. Relationship between the HLA-B* 1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol 149:9 (2013), 1025–1032.
98. Malhi, G.S., Tanious, M., Berk, M., Mania: diagnosis and treatment recommendations. Curr Psychiatry Rep 14:6 (2012), 676–686.
99. Goikolea, J., Colom, F., Capapey, J., et al. Faster onset of antimanic action with haloperidol compared to second-generation antipsychotics: a meta-analysis of randomized clinical trials in acute mania. Eur Neuropsychopharmacol 23:4 (2013), 305–316.
100. Correll, C.U., Leucht, S., Kane, J.M., Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161:3 (2004), 414–425.
101. Stanniland, C., Taylor, D., Tolerability of atypical antipsychotics. Drug Saf 22:3 (2000), 195–214.
102. Calabrese, J.R., Kimmel, S.E., Woyshville, M.J., et al. Clozapine for treatment-refractory mania. Am J Psychiatry 153:6 (1996), 759–764.
103. Medda, P., Toni, C., Perugi, G., The mood-stabilizing effects of electroconvulsive therapy. J ECT 30:4 (2014), 275–282.
104. Bartoli, F., Crocamo, C., Clerici, M., Carra, G., Allopurinol as add-on treatment for mania symptoms in bipolar disorder: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 210:1 (2017), 10–15.
105. Talaei, A., Pourgholami, M., Khatibi-Moghadam, H., et al. Tamoxifen: a protein kinase C inhibitor to treat mania: a systematic review and meta-analysis of randomized, placebo-controlled trials. J Clin Psychopharmacol 36:3 (2016), 272–275.
106. Judd, L.L., Akiskal, H.S., Schettler, P.J., et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 60:3 (2003), 261–269.
107. Calabrese, J.R., Hirschfeld, R.M., Frye, M.A., Reed, M.L., Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sample. J Clin Psychiatry 65:11 (2004), 1499–1504.
108. Taylor, D.M., Cornelius, V., Smith, L., Young, A.H., Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. Acta Psychiatr Scand 130:6 (2014), 452–469.
109. Selle, V., Schalkwijk, S., Vazquez, G.H., Baldessarini, R.J., Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry 47:2 (2014), 43–52.
110. Durgam, S., Earley, W., Lipschitz, A., et al. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry 173:3 (2016), 271–281.
111. Cipriani, A., Hawton, K., Stockton, S., Geddes, J.R., Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ, 346, 2013, f3646 http://www.bmj.com/content/346/bmj.f3646.long Accessed June 17, 2017.
112. Bond, D.J., Lam, R.W., Yatham, L.N., Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis. J Affect Disord 124:3 (2010), 228–234.
113. Geddes, J.R., Calabrese, J.R., Goodwin, G.M., Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 194:1 (2009), 4–9.
114. Tohen, M., Goldberg, J.F., Gonzalez-Pinto Arrillaga, A.M., et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 60:12 (2003), 1218–1226.
115. Thase, M.E., Jonas, A., Khan, A., et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 28:1 (2008), 13–20.
116. Lombardo, I., Sachs, G., Kolluri, S., et al. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?. J Clin Psychopharmacol 32:4 (2012), 470–478.
117. Yatham, L.N., Kennedy, S.H., Parikh, S.V., et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 15:1 (2013), 1–44.
118. Bobo, W.V., Voort, J.L., Croarkin, P.E., et al. Ketamine for treatment-resistant unipolar and bipolar major depression: critical review and implications for clinical practice. Depress Anxiety 33:8 (2016), 698–710.
119. Pacchiarotti, I., Bond, D.J., Baldessarini, R.J., et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 170:11 (2013), 1249–1262.
120. Frye, M.A., Clinical practice: bipolar disorder: a focus on depression. N Engl J Med 364:1 (2011), 51–59.
121. Grunze, H., Vieta, E., Goodwin, G.M., et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 11:2 (2010), 81–109.
122. Suppes, T., Dennehy, E.B., Hirschfeld, R.M., et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 66:7 (2005), 870–886.
123. Sproule, B., Lithium in bipolar disorder: can drug concentrations predict therapeutic effect?. Clin Pharmacokinet 41:9 (2002), 639–660.
124. van der Loos, M.L., Mulder, P.G., Hartong, E.G., et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 70:2 (2009), 223–231.
125. Suppes, T., Hirschfeld, R.M., Vieta, E., et al. Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies. World J Biol Psychiatry 9:3 (2008), 198–211.
126. Weisler, R.H., Calabrese, J.R., Thase, M.E., et al. Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. J Clin Psychiatry 69:5 (2008), 769–782.
127. Swartz, H.A., Thase, M.E., Pharmacotherapy for the treatment of acute bipolar II depression: current evidence. J Clin Psychiatry 72:3 (2011), 356–366.
128. Sidor, M.M., Macqueen, G.M., Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry 72:2 (2011), 156–167.
129. Gijsman, H.J., Geddes, J.R., Rendell, J.M., Nolen, W.A., Goodwin, G.M., Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 161:9 (2004), 1537–1547.
130. Thase, M.E., Antidepressants and rapid-cycling bipolar II disorder: dogma, definitions and deconstructing discrepant data. Br J Psychiatry 202:4 (2013), 251–252.
131. Frye, M.A., Helleman, G., McElroy, S.L., et al. Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry 166:2 (2009), 164–172.
132. Valenti, M., Pacchiarotti, I., Bonnin, C.M., et al. Risk factors for antidepressant-related switch to mania. J Clin Psychiatry 73:2 (2012), e271–e276.
133. Bond, D.J., Noronha, M.M., Kauer-Sant'Anna, M., et al. Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. J Clin Psychiatry 69:10 (2008), 1589–1601.
134. Vieta, E., Gunther, O., Locklear, J., et al. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 14:8 (2011), 1029–1049.
135. Fountoulakis KN, Yatham L, Grunze H, et al. The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), part 2: review, grading of the evidence, and a precise algorithm [published ahead of print December 22, 2016]. Int J Neuropsychopharmacol. http://dx.doi.org/10.1093/ijnp/pyw100.
136. Smith, L.A., Cornelius, V., Warnock, A., et al. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord 9:4 (2007), 394–412.
137. Cipriani, A., Reid, K., Young, A.H., et al. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev(10), 2013, CD003196.
138. Quiroz, J.A., Yatham, L.N., Palumbo, J.M., et al. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 68:2 (2010), 156–162.
139. Altshuler, L., Suppes, T., Black, D., et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 160:7 (2003), 1252–1262.
140. Zhang, Y., Yang, H., Yang, S., et al. Antidepressants for bipolar disorder: a meta-analysis of randomized, double-blind, controlled trials. Neural Regen Res 8:31 (2013), 2962–2974.
141. Fountoulakis, K.N., Kontis, D., Gonda, X., Yatham, L.N., A systematic review of the evidence on the treatment of rapid cycling bipolar disorder. Bipolar Disord 15:2 (2013), 115–137.
142. Kupka, R.W., Luckenbaugh, D.A., Post, R.M., et al. Rapid and non-rapid cycling bipolar disorder: a meta-analysis of clinical studies. J Clin Psychiatry 64:12 (2003), 1483–1494.
143. Scott, J., Colom, F., Vieta, E., A meta-analysis of relapse rates with adjunctive psychological therapies compared to usual psychiatric treatment for bipolar disorders. Int J Neuropsychopharmacol 10:1 (2007), 123–129.
144. Altman, S., Haeri, S., Cohen, L.J., et al. Predictors of relapse in bipolar disorder: a review. J Psychiatr Pract 12:5 (2006), 269–282.
145. Miklowitz, D.J., Adjunctive psychotherapy for bipolar disorder: state of the evidence. Am J Psychiatry 165:11 (2008), 1408–1419.
146. Miklowitz, D.J., Otto, M.W., Frank, E., et al. Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry 64:4 (2007), 419–426.
147. Scott, J., Pope, M., Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry 63:5 (2002), 384–390.
148. Pompili, M., Venturini, P., Palermo, M., et al. Mood disorders medications: predictors of nonadherence: review of the current literature. Expert Rev Neurother 13:7 (2013), 809–825.
149. Garcia, S., Martinez-Cengotitabengoa, M., Lopez-Zurbano, S., et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol 36:4 (2016), 355–371.
150. Fisher, A., Manicavasagar, V., Kiln, F., Juraskova, I., Communication and decision-making in mental health: a systematic review focusing on bipolar disorder. Patient Educ Couns 99:7 (2016), 1106–1120.
151. Hilty, D., Yellowlees, P.M., Parrish, M.B., Chan, S., Telepsychiatry: effective, evidence-based, and at a tipping point in health care delivery?. Psychiatr Clin North Am 38:3 (2015), 559–592.
152. Thielke, S., Vannoy, S., Unützer, J., Integrating mental health and primary care. Prim Care 34:3 (2007), 571–592.